Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Abstract : Lung cancer is the major cause of death from cancer in the world and its incidence is increasing in women. Despite the progress made in developing immunotherapies and therapies targeting genomic alterations, improvement in the survival rate of advanced stages or metastatic patients remains low. Thus, urgent development of effective therapeutic molecules is needed. The discovery of novel therapeutic targets and their validation requires high quality biological material and associated clinical data. With this aim, we established a biobank dedicated to lung cancers. We describe here our strategy and the indicators used and, through an overall assessment, present the strengths, weaknesses, opportunities and associated risks of this biobank.
Document type :
Journal articles
Complete list of metadatas

Cited literature [76 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01834086
Contributor : Laurent Jonchère <>
Submitted on : Thursday, July 18, 2019 - 3:36:30 PM
Last modification on : Wednesday, August 14, 2019 - 4:02:09 PM

File

cancers-10-00220-v2.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Kevin Washetine, Simon Heeke, Christelle Bonnetaud, Mehdi Kara-Borni, Marius Ilié, et al.. Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?. Cancers, MDPI, 2018, 10 (7), pp.E220. ⟨10.3390/cancers10070220⟩. ⟨hal-01834086⟩

Share

Metrics

Record views

42

Files downloads

28